STOCK TITAN

Collplant Biotechnologies Ltd reported $2.4M in revenue and a $11.5M net loss for fiscal 2025. See the full CLGN financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR

CollPlant closes the LightSolver acquisition, adding photonic computing and Laser Processing Unit technology alongside its regenerative medicine business.

(Very High)
(Positive)

CollPlant Biotechnologies (CLGN) completed its previously announced acquisition of Israeli deep-tech company LightSolver, formally entering the high-performance computing and photonics sectors.

LightSolver develops the Laser Processing Unit (LPU), a proprietary all‑optical, laser-based computing architecture designed to accelerate highly computational workloads such as scientific and engineering simulations, partial differential equations, large-scale linear systems and optimization. These capabilities target applications across aerospace, defense, energy, advanced engineering, financial services and Physical AI.

The transaction used an equity-centric structure. At closing, CollPlant issued upfront ordinary shares, pre-funded warrants and made a $5 million investment in LightSolver, with additional milestone-based warrants to become exercisable if specified technological and commercial objectives are achieved. CollPlant states that photonic computing activities will run alongside its existing regenerative medicine operations, which are based on its recombinant human collagen and 3D bioprinting platforms.

Loading...
Loading translation...

Positive

  • Acquisition of LightSolver completed, giving CollPlant immediate entry into high-performance computing and photonics
  • Laser Processing Unit (LPU) technology adds an all-optical platform aimed at demanding computational workloads
  • Equity-centric structure with milestone-based warrants ties part of the consideration to future technological and commercial achievements

Negative

  • Equity-based consideration including new ordinary shares, pre-funded warrants and milestone-based warrants implies potential shareholder dilution
  • $5 million cash investment into LightSolver represents capital deployment away from CollPlant’s existing uses of cash

Market Reaction – CLGN

-11.16% $0.30 423.6x vol
15m delay
-11.16% Vs previous close
$0.30 Last Price
$0.29 $0.35 Day Range
$5.77M Market Cap
423.6x Rel. Volume

Following this news, CLGN has declined 11.16%, reflecting a significant negative market reaction. Our momentum scanner has triggered 9 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.30. Trading volume is exceptionally heavy at 423.6x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Technological Edge - LightSolver advances the development of the world's first Laser Processing Unit (LPU) – an energy-efficient, pure photonic computing platform
  • Accelerated Growth Path - The transaction positions LightSolver to accelerate its path towards commercialization and expand engagements with strategic partners.

REHOVOT, Israel, Sept. 3, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) today announced the successful closing of its previously announced acquisition of LightSolver Ltd. ("LightSolver"), an Israeli deep-tech company pioneering a fundamentally new computing paradigm based on lasers.

The LightSolver photonic platform

With the closing of this transaction, CollPlant officially enters the high-performance computing (HPC) and photonics sectors. LightSolver's Laser Processing Unit (LPU) is designed to accelerate some of the most computationally demanding workloads, while the transaction provides the resources to accelerate its commercialization, expand strategic partnerships, and advance LightSolver's long-term technology roadmap.

Executive Commentary

"We are pleased to complete this transaction with LightSolver, marking CollPlant's entry into the photonics computing sector," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant. "This exciting new field of activity will run alongside our continued and active operations in regenerative medicine."

Dr. Ruti Ben Shlomi, Founder and Chief Executive Officer of LightSolver, commented, "Today marks an important milestone for our technology. We believe this next chapter will help us accelerate our technology roadmap and pursue commercial opportunities for our LPU platform globally. We remain focused on redefining the boundaries of computing speed and energy efficiency for our partners and the industry globally."

Transaction Overview

As detailed in the definitive agreement announcement on August 31, 2026, the acquisition was completed utilizing an equity-centric consideration structure. At closing, CollPlant among others issued upfront ordinary shares, pre-funded warrants and an investment of $5 million in LightSolver. Additional milestone-based warrants will become exercisable upon LightSolver's achievement of specified technological and commercial objectives.

Additional details about the transaction are available in the Company's Report on Form 6-K, which was filed with the Securities and Exchange Commission on August 31, 2026.

About LightSolver

LightSolver is an Israeli deep-tech company pioneering a new generation of high-performance computing based on the physics of light. Founded in 2020 by Weizmann Institute physicists Dr. Ruti Ben Shlomi and Dr. Chene Tradonsky, LightSolver is the developer of the Laser Processing Unit™ (LPU™), a proprietary all-optical computing architecture that uses coupled lasers to perform computation.

The LPU™ is designed to accelerate computationally intensive workloads including scientific and engineering simulation, partial differential equations, large-scale linear systems and optimization, with applications across aerospace, defense, energy, advanced engineering, financial services and Physical AI.

LightSolver is advancing its technology toward commercial deployment in collaboration with leading global organizations.

For more information about LightSolver, visit lightsolver.com.

About CollPlant

CollPlant is a pioneering technology company operating at the forefront of both regenerative medicine and advanced high-performance computing. Following the strategic acquisition of LightSolver, CollPlant has expanded its footprint into the deep-tech sector, integrating a proprietary all-optical computing architecture known as the Laser Processing Unit™ (LPU™). This bold diversification positions the Company to address some of the world's most computationally intensive workloads across aerospace, defense, and Physical AI, while continuing to drive its core biotech innovations. 

In the healthcare sector, CollPlant is ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant-based genetic engineering technology, addressing indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

For more information about CollPlant, visit collplant.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the acquisition of LightSolver by CollPlant; the anticipated benefits, strategic rationale and growth opportunities arising from the transaction; LightSolver becoming a subsidiary of CollPlant; the future development, commercialization and market adoption of LightSolver's Laser Processing Unit™ (LPU™) technology; and the future prospects, business plans and growth strategies of CollPlant, LightSolver and the combined business. Forward-looking statements can be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "may," "should," "could," "might," "seek," "target," "will," "project," "continue" and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the following: the ability of the parties to satisfy the conditions to closing the transaction and consummate the transaction on the anticipated timeline or at all; the risk that the anticipated benefits of the transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver's business, operations and personnel; LightSolver's ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver's technology; the ability to develop and commercialize LightSolver's products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant's ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contact Information:
CollPlant
Eran Rotem, Deputy CEO & CFO
Email: Eran@collplant.com
+972-73-2325600

LightSolver Ltd.
 
Dr. Ruti Ben Shlomi, Founder & CEO
Email: Ruti@lightsolver.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-completes-acquisition-of-lightsolver-entering-the-photonic-computing-sector-302868948.html

SOURCE CollPlant

FAQ

What did CollPlant (CLGN) announce regarding LightSolver?

CollPlant announced the successful closing of its previously announced acquisition of LightSolver, an Israeli deep-tech company developing a laser-based photonic computing platform, thereby marking CollPlant’s official entry into the high-performance computing and photonics sectors alongside its regenerative medicine activities.

What is LightSolver and its Laser Processing Unit acquired by CLGN?

LightSolver is an Israeli deep-tech company founded in 2020 that develops the Laser Processing Unit (LPU), a proprietary all‑optical computing architecture using coupled lasers to perform computation. The LPU is designed to accelerate workloads such as simulations, partial differential equations, large-scale linear systems and optimization.

How is the CollPlant (CLGN) acquisition of LightSolver structured financially?

The acquisition uses an equity-centric consideration structure. At closing, CollPlant issued upfront ordinary shares and pre-funded warrants and made a $5 million investment in LightSolver. Additional milestone-based warrants will become exercisable if LightSolver achieves specified technological and commercial objectives.

What strategic benefit does the LightSolver deal bring to CollPlant (CLGN)?

CollPlant states that acquiring LightSolver expands its operations into high-performance computing and photonics via the Laser Processing Unit platform. This diversification is intended to address computationally intensive workloads across aerospace, defense, energy, advanced engineering, financial services and Physical AI, while CollPlant continues its core regenerative medicine business.

Which types of applications can LightSolver’s LPU, now under CollPlant (CLGN), target?

LightSolver’s LPU is designed for computationally intensive workloads including scientific and engineering simulations, partial differential equations, large-scale linear systems and optimization. Targeted application areas include aerospace, defense, energy, advanced engineering, financial services and Physical AI use cases.

Does the CollPlant (CLGN) acquisition of LightSolver affect its regenerative medicine operations?

CollPlant’s CEO stated that the new photonic computing activity will run alongside its ongoing regenerative medicine operations. The company continues to focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics based on its recombinant human collagen technology.

Where can investors find more details on the CollPlant (CLGN) and LightSolver transaction?

Additional details on the LightSolver acquisition are available in CollPlant’s Report on Form 6-K, which was filed with the U.S. Securities and Exchange Commission on August 31, 2026 and describes the definitive agreement and transaction terms in more detail.